FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147077679> ?p ?o ?g. }

• W2147077679 abstract "Targeted radionuclide therapy with high-energy beta-emitters is generally considered suboptimal to cure small tumours (<300 mg). Tumour targeting of the CCK2 receptor-binding minigastrin analogue PP-F11 was determined in a tumour-bearing mouse model at increasing peptide amounts. The optimal therapy was analysed for PP-F11 labelled with 90Y, 177Lu or 213Bi, accounting for the radionuclide specific activities (SAs), the tumour absorbed doses and tumour (radio) biology. Tumour uptake of 111In-PP-F11 was determined in nude mice bearing CCK2 receptor-transfected A431 xenografts at 1 and 4 h post-injection for escalating peptide masses of 0.03 to 15 nmol/mouse. The absorbed tumour dose was estimated, assuming comparable biodistributions of the 90Y, 177Lu or 213Bi radiolabelled peptides. The linear-quadratic (LQ) model was used to calculate the tumour control probabilities (TCP) as a function of tumour mass and growth. Practically achievable maximum SAs for PP-F11 labelled with 90Y and 177Lu were 400 MBq 90Y/nmol and 120 MBq177Lu/nmol. Both the large elution volume from the 220 MBq 225Ac generator used and reaction kinetics diminished the maximum achieved 213Bi SA in practice: 40 MBq 213Bi/nmol. Tumour uptakes decreased rapidly with increasing peptide amounts, following a logarithmic curve with ED50 = 0.5 nmol. At 0.03 nmol peptide, the (300 mg) tumour dose was 9 Gy after 12 MBq 90Y-PP-F11, and for 111In and 177Lu, this was 1 Gy. A curative dose of 60 Gy could be achieved with a single administration of 111 MBq 90Y labelled to 0.28 nmol PP-F11 or with 4 × 17 MBq 213Bi (0.41 nmol) when its α-radiation relative biological effectiveness (RBE) was assumed to be 3.4. Repeated dosing is preferable to avoid complete tumour receptor saturation. Tumours larger than 200 mg are curable with 90Y-PP-F11; the other radionuclides perform better in smaller tumours. Furthermore, 177Lu is not optimal for curing fast-growing tumours. Receptor saturation, specific radiopharmaceutical activities and absorbed doses in the tumour together favour therapy with the CCK2 receptor-binding peptide PP-F11 labelled with 90Y, despite its longer β-particle range in tissue, certainly for tumours larger than 300 mg. The predicted TCPs are of theoretical nature and need to be compared with the outcome of targeted radionuclide experiments." @default.
• W2147077679 created "2016-06-24" @default.
• W2147077679 creator A5000332171 @default.
• W2147077679 creator A5000855050 @default.
• W2147077679 creator A5007539874 @default.
• W2147077679 creator A5011219611 @default.
• W2147077679 creator A5012764804 @default.
• W2147077679 creator A5034821195 @default.
• W2147077679 creator A5036402316 @default.
• W2147077679 creator A5040369608 @default.
• W2147077679 creator A5065299486 @default.
• W2147077679 date "2014-08-30" @default.
• W2147077679 modified "2023-10-09" @default.
• W2147077679 title "Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount" @default.
• W2147077679 cites W1529490909 @default.
• W2147077679 cites W1831460023 @default.
• W2147077679 cites W1933764379 @default.
• W2147077679 cites W1981017683 @default.
• W2147077679 cites W1982055976 @default.
• W2147077679 cites W1987319381 @default.
• W2147077679 cites W2008719853 @default.
• W2147077679 cites W2009041257 @default.
• W2147077679 cites W2014085992 @default.
• W2147077679 cites W2014544986 @default.
• W2147077679 cites W2016475051 @default.
• W2147077679 cites W2020714798 @default.
• W2147077679 cites W2024031072 @default.
• W2147077679 cites W2032747682 @default.
• W2147077679 cites W2046701188 @default.
• W2147077679 cites W2047558841 @default.
• W2147077679 cites W2051563205 @default.
• W2147077679 cites W2074094034 @default.
• W2147077679 cites W2075075102 @default.
• W2147077679 cites W2087620192 @default.
• W2147077679 cites W2089936245 @default.
• W2147077679 cites W2092689990 @default.
• W2147077679 cites W2102373740 @default.
• W2147077679 cites W2110575681 @default.
• W2147077679 cites W2112262688 @default.
• W2147077679 cites W2112884695 @default.
• W2147077679 cites W2115592182 @default.
• W2147077679 cites W2124325993 @default.
• W2147077679 cites W2124902448 @default.
• W2147077679 cites W2125398839 @default.
• W2147077679 cites W2132674867 @default.
• W2147077679 cites W2152066848 @default.
• W2147077679 cites W2152279343 @default.
• W2147077679 cites W2161644780 @default.
• W2147077679 cites W2256938482 @default.
• W2147077679 cites W2313580829 @default.
• W2147077679 doi "https://doi.org/10.1186/s13550-014-0047-1" @default.
• W2147077679 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4452684" @default.
• W2147077679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26116111" @default.
• W2147077679 hasPublicationYear "2014" @default.
• W2147077679 type Work @default.
• W2147077679 sameAs 2147077679 @default.
• W2147077679 citedByCount "20" @default.
• W2147077679 countsByYear W21470776792015 @default.
• W2147077679 countsByYear W21470776792016 @default.
• W2147077679 countsByYear W21470776792017 @default.
• W2147077679 countsByYear W21470776792018 @default.
• W2147077679 countsByYear W21470776792019 @default.
• W2147077679 countsByYear W21470776792020 @default.
• W2147077679 countsByYear W21470776792021 @default.
• W2147077679 countsByYear W21470776792023 @default.
• W2147077679 crossrefType "journal-article" @default.
• W2147077679 hasAuthorship W2147077679A5000332171 @default.
• W2147077679 hasAuthorship W2147077679A5000855050 @default.
• W2147077679 hasAuthorship W2147077679A5007539874 @default.
• W2147077679 hasAuthorship W2147077679A5011219611 @default.
• W2147077679 hasAuthorship W2147077679A5012764804 @default.
• W2147077679 hasAuthorship W2147077679A5034821195 @default.
• W2147077679 hasAuthorship W2147077679A5036402316 @default.
• W2147077679 hasAuthorship W2147077679A5040369608 @default.
• W2147077679 hasAuthorship W2147077679A5065299486 @default.
• W2147077679 hasBestOaLocation W21470776791 @default.
• W2147077679 hasConcept C126894567 @default.
• W2147077679 hasConcept C138944611 @default.
• W2147077679 hasConcept C185592680 @default.
• W2147077679 hasConcept C2779281246 @default.
• W2147077679 hasConcept C2989005 @default.
• W2147077679 hasConcept C2993559085 @default.
• W2147077679 hasConcept C502942594 @default.
• W2147077679 hasConcept C55493867 @default.
• W2147077679 hasConcept C71924100 @default.
• W2147077679 hasConcept C98274493 @default.
• W2147077679 hasConceptScore W2147077679C126894567 @default.
• W2147077679 hasConceptScore W2147077679C138944611 @default.
• W2147077679 hasConceptScore W2147077679C185592680 @default.
• W2147077679 hasConceptScore W2147077679C2779281246 @default.
• W2147077679 hasConceptScore W2147077679C2989005 @default.
• W2147077679 hasConceptScore W2147077679C2993559085 @default.
• W2147077679 hasConceptScore W2147077679C502942594 @default.
• W2147077679 hasConceptScore W2147077679C55493867 @default.
• W2147077679 hasConceptScore W2147077679C71924100 @default.
• W2147077679 hasConceptScore W2147077679C98274493 @default.
• W2147077679 hasIssue "1" @default.
• W2147077679 hasLocation W21470776791 @default.
• W2147077679 hasLocation W21470776792 @default.
• W2147077679 hasLocation W21470776793 @default.

• next